Harvard researchers have developed a faster, cheaper CRISPR-based genetic screening method that uniformly edits genes across entire organoids — no tedious clone selection required. Testing it on 77 genes linked to brain development, they pinpointed three key genes (ZIC2, SOX11, ZNF521) that drive neural tube closure. The findings could open new doors for understanding — and treating — serious birth defects like anencephaly.
Harvard researchers have unveiled a streamlined CRISPR-based genetic screening platform that can uniformly knock down individual genes across entire organoid tissues — a feat that was previously too slow, costly, or technically impractical. Published as a landmark study in eLife, the method sidesteps the usual bottleneck of isolating and cultivating individually edited cell clones, instead using optimized viral delivery to achieve near-complete gene editing across human pluripotent stem cell (hPSC)-derived organoids.
The team applied the tool to study neural tube development — a critical early brain-forming process whose failure causes fatal birth defects like anencephaly. Screening 77 candidate genes, they identified three — ZIC2, SOX11, and ZNF521 — as key drivers of neural tube closure, each controlling a cascade of downstream genes.
Key Takeaways:
Why it matters: This platform bridges a critical gap between animal model genetics and human developmental biology, offering a powerful new tool for uncovering the mechanisms behind congenital malformations and identifying potential therapeutic targets.
